Table 2.
Metabolites with a significant unadjusted interaction with medication group on relative HbA1c change in the entire study population (n = 264)
| Metformin | Sulphonylurea (SU) | Metformin and SU | ||||
|---|---|---|---|---|---|---|
| Coefficient | p value | Coefficient | p value | Coefficient | p value | |
| 1,5 anhydroglucitol (HMDB 02712, CAS 154-58-5) | 14.2 | 0.001 | 10.8 | 0.043 | 29.8 | <0.0001 |
| 2-hydroxybutanoic acid (HMDB 00008, CAS 5094-24-6) | −60.7 | 0.011 | 14.6 | 0.716 | −68.5 | 0.013 |
| 2-hydroxypiperidine (Pubchem 24847875, CAS 5382-16-1) | 781.4 | 0.016 | 333.5 | 0.511 | 1164.2 | 0.002 |
| 3-hydroxybutanoic acid (HMDB 00357, CAS 300-85-6) | −18.2 | 0.029 | −4.6 | 0.850 | −54.3 | 0.015 |
| 4-oxoproline (KEGG C01877, CAS 4347-18-6) | 517.9 | 0.002 | 409.5 | 0.096 | 682.0 | 0.001 |
| Glucose (HMDB 00122, CAS 50-99-7) | −1.7 | 0.001 | −1.3 | 0.043 | −1.8 | 0.0003 |
| Glutamic acid internal amidea (HMDB 00267, CAS 98-79-3) | 26.6 | <0.0001 | 9.8 | 0.296 | 15.6 | 0.026 |
| Myo-inositol (HMDB 00211, CAS 87-89-8) | 51.3 | 0.050 | 6.7 | 0.818 | 106.0 | 0.038 |
| Pseudo uridine (HMDB 00767, CAS 1445-07-4) | 109.3 | 0.012 | 35.1 | 0.519 | 140.1 | 0.007 |
| LCB 18:1-17:0 SM | 1079.0 | 0.044 | 409.7 | 0.586 | 1830.9 | 0.003 |
| l-Methionine (HMDB 00696, CAS 63-68-3) | 191.1 | 0.018 | 101.8 | 0.363 | 25.1 | 0.768 |
| l-Phenylalanine (HMDB 00159, CAS 63-91-2) | 24.3 | 0.034 | 17.0 | 0.317 | 2.5 | 0.843 |
| 4-Hydroxyglutamate semialdehyde (HMDB 06556) | 654.1 | 0.034 | 527.3 | 0.192 | 457.6 | 0.162 |
| LCB18:0-16:0 SM (HMDB 10168) | 30.2 | 0.334 | 33.3 | 0.500 | 93.5 | 0.010 |
| LCB18:1-18:0 SM (HMDB 01348, CAS 58909-84-5) | −0.9 | 0.763 | 4.5 | 0.236 | 6.6 | 0.038 |
| Uric acid (HMDB 00289, CAS 69-93-2) | 0.7 | 0.163 | 0.4 | 0.526 | 1.3 | 0.020 |
This beta represents the additional contribution of each metabolite in the specific medication group compared with the no medication group
aFormed during derivatisation step, measure for glutamate